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Growth-Related Alterations during Liver
Carcinogenesis: Effect of Promoters
by Per 0. Seglen* and Per Gerlyng*
Bromodeoxyuridine labeling of DNA, binuclearity counting, and flow cytometric analysis of isolated
hepatocytes and hepatocyte nuclei has been used to assess hepatocellular growth patterns related to liver
carcinogenesis. Three growth patterns can be distinguished. Mononucleating growth is observed during
liver regeneration and after treatment with the tumor promoter 2-acetylaminofluorene (2-AAF) and its
analogue 4-AAF. In this growth mode binucleation does not occur, resulting in a decrease in the fraction
ofbinucleated cells. Binucleating growth is observed during normal liverdevelopment and aftertreatment
with compounds such as phenobarbital, characterized by progressive polyploidization and maintenance
of a binucleated cell fraction. Diploid growth is the growth pattern of neoplastic liver hepatocytes. Most
of the cells in neoplastic lesions (foci, nodules, and carcinomas) are diploid, in contrast to the normal
liver. Diploid tumor cells have a much higher proliferative activity than tetraploid tumor cells, suggesting
that the latter may posses a limited growth potential that makes abrogation ofbinucleation proliferatively
advantageous.
Introduction
Cancer is basically agrowth control disease, and liver
cancer is no exception. In experimental liver carcino-
genesis, altered growth control has been described at
several stages. Early, phenotypically altered hepato-
cellular foci, induced by an initiating carcinogen such as
diethylnitrosamine (DEN), exhibit in general a normal
or moderately elevated rate ofproliferation during the
first few months of their existence. The altered foci
respond relatively normally to various liver growth
stimuli (1-5). However, the focal hepatocytes prolif-
erate particularly vigorously in response to the liver
tumor promoter 2-acetylaminofluorene (2-AAF),
whereas normal hepatocytes do not (5-7). A minority
of the foci (those with the most complex phenotype)
appear to be constitutively hyperproliferative and are
probably precursors of the benign neoplastic nodules
that eventually develop (4). These nodules have a high
rate of proliferation and cell turnover and show an ex-
tended regenerative response (8).
At the hepatocellular carcinoma stage, a multitude of
growth-related alterations have been described. These
include expression of activated ras oncogenes (9,10);
hyperexpression of c-myc and other proto-oncogenes
(11-13); growth receptor alterations (14-16), and syn-
thesis ofgrowth factors not normally produced by adult
hepatocytes, such as IGF-II (17), bFGF (18), bombesin
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(19), and others (20,21). Some ofthese changes may be
regarded as aspects oftumor progression, contributing
to increasing tumorgrowth rate and autonomy through
the establishment of autocrine circuits.
Despite our increasing knowledge about peripheral
effectoralterationsinhepatocellulartumors, thebasic
mechanisms of liver growth control remain poorly
understood. Growth in a specialized tissue is an in-
tegral part of the specific differentiation program of
that tissue, and in the adult liver, hepatocytic prolif-
eration is uniquely characterized by extensive poly-
ploidization (22). This pattern is replaced by nonpo-
lyploidizing growth during the rapid regeneration
following partial hepatectomy (23), whereas in hepa-
tocellular tumors growth occurs mainly by divisional
proliferation of diploid cells (24). The functional sig-
nificance and selective control ofthese various growth
patterns is not known.
Growthpatternalterations aredetectable atthe early
stages of DEN/2-AAF-induced liver carcinogenesis
(25). We have sought to analyze growth patterns
throughoutthe carcinogenicdevelopmentprocess, mak-
ing comparisons with the proliferative strategies em-
ployedbynormalhepatocytes. Theeffectsoflivertumor
promoters have been given particular emphasis. Al-
though most tumor promoters are believed to act pri-
marily as specific growth stimulants, other mechanisms
of action cannot be excluded (26,27). In the case of 2-
AAF, ithasbeensuggestedthatthegrowthofabnormal
cells might be stimulated indirectly, depending on cy-
totoxic inhibition ofnormal hepatocytes and the release
ofa compensatory regenerative signal (28). Analysis of
hepatocellular growth patterns following treatmentSEGLEN AND GERLYNG
with 2-AAF and related compounds could help to elu-
cidate the mechanism of action of this important liver
tumor promoter.
Promotion of Primary and
Secondary Liver Carcinogenesis by
2-AAF: Stimulation of Neoplastic
Cell Growth
In most of our work we have used rats ofthe inbred
Wistar Kyoto strain in order to permit transplantation
experiments. Our carcinogen treatment protocol used
the very effective combination oftwo-thirds partialhep-
atectomy (PH) and DEN (50 mg/kg) for initiation (29),
followed after 1 weekofregeneration by a4-weektreat-
ment with dietary 2-AAF (0.01-0.02%) as a promoter
(25). It should be noted that 2-AAF is a carcinogenic
compound, with potentially initiating as well as pro-
moting properties. When given at high doses for a long
time 2-AAF can be strongly tumorigenic (30), but when
administered at moderate doses (0.01-0.02% in the diet
for 4 weeks or less) in the absence of additional prolif-
erative stimuli, carcinoma formation is very late in oc-
currence and low in incidence (31).
The promoting effect of2-AAF was detectable bythe
end ofthe treatmentperiod as anincrease inthenumber
ofenzymatically altered hepatocytes stainingpositively
for the enzyme -y-glutamyltranspeptidase (GGT) (31).
The GGT-positive cells, which have a focal distribution
in the intact liver, can be precisely quantitated in he-
patocyte suspensions prepared bycollagenase perfusion
(25). Whilevirtuallyundetectableinnoninitiated or non-
promoted animals, as many as 30% of the hepatocytes
were GGT-positive in rats that had received the com-
plete carcinogen treatment (Table 1).
Promotion by 2-AAF was also evident at the tumor
level. Four months after initiation, the number oflarge
neoplastic nodules (,: 1 mm in diameter) was 10 times
higher in rats given the promoter, and at 8 months the
promoted animals had 3 times as many hepatocellular
carcinomas as the nonpromoted ones (Table 1). Consid-
ering that the 2-AAF treatment had been terminated
after 5 weeks, the effect ofthis promoter on liver car-
cinogenesis can be regarded as effectively irreversible.
The irreversibility was furthermore reflected in the
long-termpersistence ofamajorfraction ofthe enzyme-
altered (GGT-positive) hepatocytes (31).
If2-AAF promoted liver carcinogenesis by stimulat-
ingthe growth ofneoplastic hepatocytes, we might per-
haps expect 2-AAF responsiveness to be retained even
in established hepatocarcinoma cells. To examine this
possibilityindependentlyofanyspecificearly-stage pro-
motion, cell suspensions from primary hepatocellular
carcinomas were transplanted by intraportal injection
(32) to syngeneic recipients. In the host livers, out-
growth of secondary carcinomas was indeed strongly
promoted by 2-AAF as well as by another liver tumor
promoter, phenobarbital (Table 2).
2-AAF would thus seem to act as a stimulant of neo-
plastic cell growth, much like the other known liver
tumor promoters (3). By virtue of its ability to inhibit
normal hepatocyte proliferation following a partial hep-
atectomy (5,6), 2-AAF may show greater selectivity
than other tumor promoters, which also effectively in-
duce hyperplasia of the normal liver (3). The fact that
even established cancer cells are stimulated provides a
somewhat simplified concept oftumor promotion, since
no stage-specific mechanisms need to be invoked. Pro-
moters are simply growth stimulants, and any specific-
ityintermsofextent ordurationofthegrowth response
will have to reside with the responding cell.
Table 1. Promoting effect of 2-AAF on the development of preneoplastic, GGT-positive hepatocytes, neoplastic nodules, and
hepatocellular carcinomas in Wistar Kyoto rats initiated by PH and DEN (31).
Time after
Lesion type PH + DEN Without 2-AAFa With 2-AAFa
GGT-positive cells, % 6 weeks 0.0 ± 0.0 (2) 29.1 ± 3.8 (4)*
Nodules (- 1 mm)/animal 4 months 1.4 ± 0.5 (5) 14 ± 3 ( 1)"
Hepatocellular carcinomas/animal 8 months 0.8 ± 0.3 (6) 2.4 ± 0.4 (8)t
aValues are means ± SE; number of animals given in parentheses.
*p < 0.001, Student's t-test.
tp < 0.02, Student's t-test.
Table 2. Effect of tumor promoters on outgrowth of secondary hepatocellular carcinomas."
Recipient Harvest % cancer incidence No. oftumors/ Total tumor mass/
treatment time (animals/total) animal animal, mg
None (PH) 2 months 62 (13/21) 9.5 ± 6.3 31 ± 17
2-AAF 2 months 90 (18/20) 42.0 ± 12.6* 398 ± 159t
PB 2 months 100 (19/19)t 101.8 ± 35.1t 1608 ± 721*
aDonor rats received ful carcinogen treatment (PH + DEN + 2-AAF), and after 8 months cell suspensions were prepared fromhepatocellular
carcinomas and transplanted by intraportal injection (of500,000 viable cells) to partially hepatectomized (PH) syngeneic recipients. The recipients
were subjected to secondary promotion with 2-AAF or phenobarbital (PB) as indicated. From Seglen et al. (39), with minor corrections.
*p < 0.05, Student's t-test.
tp < 0.02, Student's t-test.
tp < 0.005, Student's t-test.
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Direct or Indirect Growth
Stimulation by 2-AAF?
The observations that 2-AAF promoted the nodular
outgrowth ofDEN-altered cells particularly effectively in
the partially hepatectomized liver, while simultaneously
suppressing the proliferation of normal hepatocytes, led
Farber (6) to propose differential cytotoxicity as the driv-
ing force ofpromotion. Hepatocellular tumors-and pre-
sumably their cellular precursors-are characteristically
drug resistant due to high expression of the multidrug
resistance (rndr) gene (33) and various drug-metabolizing
enzymes (34). Initiated cells might therefore resist the
cytotoxic effects exerted by 2-AAF upon normal hepa-
tocytes in the partially hepatectomized liver (6,35), ena-
blingthe initiated cells to proliferate selectively under the
prolonged regenerative stimulus provided by the cyto-
toxic conditions. However, several authors found that 2-
AAF could promote liver carcinogenesis even under con-
ditions where no hepatotoxicity was evident, as when the
drug was administered in the absence of or after a partial
hepatectomy (31,36). Such results would seem to indicate
that 2-AAF can promote by a mechanism independent of
cytotoxicity.
2-AAF exhibits significant systemic toxicity, as indi-
cated by a20% lowerbodyweight intreated animals even
3 weeks after cessation oftreatment (Table 3). However,
the drug was apparently not detectably hepatotoxic in our
experimental protocol, since the liver grew at the same
rate asincontrolIanimals throughout thetreatment period
(31). The liver weight, protein content, and DNA content
was thus normal 3 weeks after cessation of treatment
(Table3). Thelackof2-AAF hepatotoxicity contrasts with
the previously observed suppression ofnornalhepatocyte
growth in partially hepatectomized Fischer rats (6), and
mayreflect alower2-AAF sensitivityintheWistarKyoto
strain as well as the fact that treatment in the present
experiments was begun some time after partial hepatec-
tomy. Hepatocytes have been found to exhibit increased
drug resistance after liver regeneration (37), possibly be-
cause ofelevated expression ofthe mdr gene (38). In any
case, promotion of carcinogenesis by 2-AAF in our ex-
periments would seem to be effected by a noncytotoxic
mechanism.
2-AAF Alters the Hepatocellular
Growth Pattern
Although 2-AAF neither inhibits nor stimulates prolif-
eration of normal hepatocytes under our experimental
conditions, it can nevertheless be shown to affect hepa-
tocytic growth (23). A combined flow cytometric and light
microscopic analysis of hepatocytic cell suspensions and
isolated nuclei (Table 4) revealed that 2-AAF treatment
markedly altered hepatocellular ploidy distributions (23).
Themoststrildngchanges were adecreaseinthefractions
of binucleated cells and an increase in the diploid cell
fraction. These changes resemble the ones observed dur-
ing liver regeneration (Table 4) and can best be described
Table 3. Systemic toxicity, but no hepatotoxicity, of 2-AAF
given to young male rats 1 to 5 weeks after partial
hepatectomy.a
Parameter Without 2-AAF With 2-AAF
Body weight, g 320.0 ± 10.4 264.8 ± 4.9*
Liver weight, g 9.7 ± 0.4 9.7 ± 0.4
Liver dry mass, mg 2439 ± 159 2362 ± 81
Liver protein, mg 1842 ± 102 1689 ± 55
Liver DNA, mg 15.8 ± 0.7 15.3 ± 0.2
aRats weighing 70 g were subjected to two-thirds partial hepatec-
tomy, given 0.02% dietary 2-AAF from 1 to 5 weeks, and sacrificed at
8 weeks. Each value is the mean ± SE of three animals.
*p < 0.01, Student's t-test.
Table 4. Similar alterations in hepatocellular ploidy
distributions after 2-AAF treatment and liver regeneration.a
Group 2N 2 x 2N 4N 2 x 4N 8N
Control 11.2 10.9 54.6 13.2 10.0
2-AAF 38.5 2.7 53.5 1.0 4.4
Before regeneration 25.7 22.6 39.8 8.7 3.1
After regeneration 38.1 4.9 51.5 1.7 3.8
aCellularand nuclearploidymeasurements weremadeimmediately
before or 1 week after partial hepatectomy, or at 6 weeks with or
without intermediary 2-AAF feeding (1-5 weeks). Calculated cell
class distributions from Saeter et al. (23).
as a switch from a binucleating (polyploidizing) to a mon-
onucleating (nonpolyploidizing) mode ofgrowth (23). An-
other liver tumor promoter, phenobarbital, has been
found to stimulate net growth (limited hyperplasia) ofthe
normal liver without altering hepatocellular ploidy distli-
butions (39). Different tumor promoters would therefore
appear capable of eliciting different proliferation pro-
grams in the liver.
Stimulation of Hepatocellular
Growth by the Analogue 4-AAF
The ability of2-AAF to alterthe livergrowth pattern
without actually stimulatinglivergrowth could possibly
be the net result oftwo opposingeffects: a specific stim-
ulation of mononucleating growth and a simultaneous
inhibition of binucleating growth (or a more general
suppression of hepatocytic proliferation) masking the
stimulation. In an attempt to examine this hypothesis
indirectly, we administered the analogue 4-AAF, which
has been reported to be noncytotoxic (40) and to stim-
ulate DNA synthesis in normal liver (41). As shown in
Table 5, 4-AAF, like phenobarbital (but unlike 2-AAF),
stimulated liver growth as measured by either mass,
protein content, or DNA content.
To see if4-AAF could alterthe hepatocellulargrowth
pattern in a manner similar to 2-AAF, we gave rats a
single high dose of4-AAF and measured the fraction of
binucleated hepatocytes, the most sensitive indicator of
changes ofthis kind, at different time points during the
following 2 days. Hepatocytic proliferation activity
(DNAlabelingindex)wassimultaneouslymonitoredim-
munocytochemically (42) as the incorporation of bro-
modeoxyuridine (BrdU) into hepatocyte nuclei. BrdU
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Table 5. Liver hyperplasia induced by 2-AAF, 4-AAF, and phenobarbital.a
Treatment Liver weight, g Protein, g/liver DNA, mg/liver
Control (2 weeks) 6.00 ± 0.22 (4) 1.24 ± 0.02 (4) 15.2 ± 0.3 (4)
2-AAF (0.01%, 2 weeks) 5.61 ± 0.32 (4) 1.16 ± 0.04 (4) 14.9 ± 0.6 (4)
4-AAF (0.1%, 2 weeks) 6.90 ± 0.26 (4)* 1.38 ± 0.04 (4)* 19.6 ± 0.4 (4)t
Phenobarbital (0.04%, 2 weeks) 7.66 ± 0.19 (4)t 1.50 ± 0.05 (4)t 20.3 ± 0.2 (4)t
aRats 4 weeks old, weighing 70 g, were given dietary 2-AAF, 4-AAF, or phenobarbital for 2 weeks. Values are the means ± SE; number of
animals given in parentheses.
* p < 0.05, Student's t-test.
tp < 0.001, Student's t-test.
tp < 0.005, Student's t-test.
was administered in the form of solid tablets (43) de-
posited SC at regular intervals, using labeling periods
from 8 to 60 hr.
About 30 hr after oral administration of 4-AAF, a
precipitous drop in the binucleated fraction was ob-
served (Table 6). Division ofbinucleated cells gives rise
to mononucleated progeny of higher ploidy (22); these
cells therefore need to be formed by de novo binuclea-
tion at the same rate as they divide to remain as a
constant fraction of the hepatocyte population. The
stimulation ofproliferationby4-AAF clearly upsets this
balance. There are two basically different mechanisms
by which binucleated cells might disappear: by selective
stimulation oftheir proliferation in excess ofreplenish-
ment through binucleation, orby an absolute orrelative
inhibition ofbinucleation. Inthe latter case, the fraction
ofbinucleated cells would decrease both bydilution with
mononucleated cellsand as aresultoftheir owndivision.
The results in Table 6 tend to support the second al-
ternative: the binucleated cells are not specifically stim-
ulated by 4-AAF; their labeling index is in fact signif-
icantly lower than that of the mononucleated cells. 4-
AAF would thus seem to induce a mononucleating type
of growth, causing binucleated to disappear by a com-
bination of dilution and division.
Long-term treatment with 4-AAF caused an even
more pronounced reduction in the fraction of binu-
Table 6. Reduced fraction of binucleated hepatocytes after
4-AAF treatment: proliferative activity of binucleated and
mononucleated cells.a
Time
after
4-AAF
No. of
animals
Percentage of
binucleated Labelig idex, %
hepatocytes Mononucleated Binucleated
7-15 hr 3 27.1 ± 1.7 0.6 ± 0.6 0.5 ± 0.5
15-31 hr 6 27.1 ± 1.4 17.7 ± 2.9 7.2 ± 1.6*
31-47 hr 6 14.9 ± 1.6 25.2 ± 1.3 7.5 ± 2.4t
a Rats were given a single dose of4-AAF (1000 mg/kg), and a pulse
of BrdU 8 hr before sacrifice. Binuclearity and labeling index (per-
centage of BrdU-positive cells) were measured by light microscopy.
The two latter time intervals include pooled values from pulse periods
each (15-23 hr and 23-31 hr in the second interval; 31-39 hr and 39-
47 hr in the third). Each value is the mean ± SE of three or six
animals.
*Binucleated labeling index significantly lowerthanmononucleated
labeling index at p < 0.01, Student's t-test.
t Binucleated labeling index significantly lowerthan mononucleated
labeling index at p < 0.001, Student's t-test.
Table 7. Effect of4-week treatment with 2-AAF or 4-AAF on
hepatocytic binuclearity, labeling index, and percentage of
diploid nuclei.a
% Hepatocytic
No. of Binucleated % Diploid labeling
Treatment animals hepatocytes nuclei index
None 3 20.1 ± 0.6 44.2 ± 1.6 0.6 ± 0.3
2-AAF 3 6.7 ± 0.4 45.9 ± 1.5 3.1 ± 0.9
4-AAF 3 3.9 ± 0.1 46.2 ± 1.1 2.4 ± 0.6
DEN 4 18.4 ± 1.2 51.5 ± 1.4 1.1 ± 0.3
DEN + 2-AAF 4 4.3 ± 1.0* 64.4 ± 4.1t 11.7 ± 1.3*
DEN + 4-AAF 4 4.8 ± 0.7* 68.0 ± 1.0* 9.2 ± 2.8+
aPartially hepatectomized rats were given a single initiating dose
ofDEN and/or2-AAF or4-AAF for4weeksasindicated. Binucleated
hepatocytes were counted in the light microscope; nuclear ploidy dis-
tributions by flow cytometry, and labeling index as the percentage of
BrdU-positive hepatocytes (microscope counting of isolated cells)
after a 60-hr incorporation in vivo, followed by a 12-hr chase. Each
value is the mean ± SE of three or four animals.
*p < 0.001 versus DEN alone, Student's t-test.
+p < 0.05 versus DEN alone, Student's t-test.
cleated hepatocytes both in normal and DEN-treated
liver (Table 7). These alterations were similar to those
observed with 2-AAF, whereas phenobarbital (not
shown) had no effect under the same conditions.
The growth response to 4-AAF was a limited hyper-
plasia, similar to what has been observed with other
liver growth stimulants (44). After 4 weeks of treat-
ment, the hepatocytic labeling index was thus only in-
significantly elevated in noninitiated livers (Table 7). In
DEN-initiated livers, on the other hand, the labeling
index was markedly increased both in 4-AAF-treated
and 2-AAF-treated livers. An elevated fraction of dip-
loid hepatocyte nucleiwas also evidentwithboth agents
(Table 7). In the case of 2-AAF, these changes are
known to reflect the proliferation of focal hepatocytes
(5,6), most ofwhich are diploid (23,45-47), but it would
probably be premature to conclude on the basis ofthese
preliminary data that 4-AAF similarly promotes the
outgrowth of altered hepatocytes. The eventual clas-
sification of 4-AAF as a tumor promoter will have to
await a demonstration of its actual stimulation of the
formation of hepatocellular tumors. Nevertheless, it
seems clear that 4-AAF in its role as a liver growth
stimulant induces a mononucleating growth pattern re-
sembling that observed after 2-AAF treatment. A sim-
ilar pattern change has been observed after treatment
with a liver growth-stimulating and tumor-promoting
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FIGURE 1. Flow cytometric DNA distributions of cells and nuclei from control livers 6 weeks after partial hepatectomy (PH) (A,B) and from
a hepatocellular carcinoma 32 weeks after initiation of PH/DEN/2-AAF treatment (C,D). Modified from Seter et al. (24).
steroid, cyproterone acetate (48). These results
strengthen the notion that even 2-AAF may have in-
trinsic growth-stimulatory properties that are indepen-
dent of(but in the normal liver masked by) its cytotoxic
actions. Whether 2-AAF and 4-AAF actually share a
common mechanism of growth stimulation remains to
be shown. It should be noted that 4-AAF is needed at
10 times higher concentrations than 2-AAF to be max-
imally effective, and the two compounds differ both in
theirreceptoraffinities (49) and intheirrelative abilities
to induce various drug-metabolizing enzymes (50). It is
thus conceivable that an AAF receptor with higher af-
finity for 2-AAF than for 4-AAF may mediate the stim-
ulation of neoplastic cell growth.
Diploid Growth Pattern of
Hepatocellular Tumors
Hepatocellular tumors are basically hyperprolifera-
tive lesions, but in addition to the elevated growth rate,
their abnormal growth is reflected in the pattern of
cellular growth. Whereas the normal liver grows pre-
dominantly by progressive polyploidization, both neo-
plastic nodules and hepatocellular carcinomas have a
strongly reduced tendency to polypoidize and instead
grow mainly by divisional proliferation of diploid cells
(24,25). This neoplastic growth patterns is readily ob-
served by flow cytometric analysis of isolated tumor
cells and nuclei (Fig. 1). In normal liver tissue, only
about 10% of the hepatocytes (and 20-40% of the he-
patocyte nuclei, depending on the strain- and age-de-
pendent size ofthe binuclear fraction) are diploid, while
nodules on average contain 70% diploid cells and car-
cinomas 80% diploid cells (24). We have analyzed he-
patocellular carcinomas induced by a variety of carcin-
ogenic regimens, and found a predominantly diploid
growth pattern in all cases (39). Even in human liver
cancer, a reduced polyploidization tendency is evident,
although the moderate degree ofpolyploidy in the nor-
mal human liver tissue makes the difference somewhat
less striking than in the rat (51). The emergence of
increasing numbers of diploid cells is observable at an
early stage of carcinogenesis (23,25) (Table 6).
The function ofliver polyploidy and its abrogation in
liver tumors is not entirely clear. A significant corre-
lation between tumor size and fractional content ofdip-
loid cells in synchronous liver nodules suggests that
polyploidization is associated with a reduced growth po-
tential (24). Polyploidization is an irreversible, pro-
gressively terminal differentiation process (22); the pol-
yploid cells are accordingly incapable of generating
diploid progeny and can presumably onlyundergo a lim-
ited number of divisions (52). The switch to a diploid,
divisional growth pattern in tumors would maintain a
larger population of potential stem cells and hence a
higher capacity for continual, unlimited growth. It is
noteworthy that although abnormal preneoplastic foci
of tetraploid hepatocytes have been observed (45), te-
traploid liver tumors have never been reported, sup-
porting the contention of a limited proliferation poten-
tial in polyploid cells.
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FIGURE 2. Flow cytometric DNA distributions ofhepatocytic nuclei
from regenerating rat liver stained with the fluorescent dye
Hoechst 33258. (A)-Unquenched pattern, 23 hr after partial hep-
atectomy (PH). (B) Animals treated with BrdU for 8 hr before
sacrifice, 23 hr after-PH. Notice strongly quenched 4N and 8N
subpopulations (BrdU-labeled nuclei inlate SandG2phase)located
far below the respective unquenched peaks. (C) 8 hr-BrdU pulse
followed by 12 hr chase; sacrifice 35 hr after PH. Notice quenched
2N and 4N subpopulations (divided BrdU-labeled nuclei) posi-
tioned below the respective unquenched peaks; also notice the
reappearance of the unquenched 8N peak.
Proliferative Activity of Different
Ploidy Classes in Normal Liver and
Hepatocellular Carcinoma
To furtherinvestigate the proliferative activity ofthe
different hepatocytic ploidy classes, we used flow cy-
tometric analysis of BrdU-labeled cells. The principle
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FIGURE 3. Flow cytometric DNA distributions of nuclei from he-
patocellular carcinoma 16 months after PH and 2-AAF treatment.
Hoechst 33258 staining; 60 hr BrdU incorporation and 12hr chase.
Notice quenched peak (divided BrdU-labeled diploid nuclei) below
the unquenched 2N peak.
Table 8. Hepatocellular growth patterns.
Mononucleating growth (regeneration, 2-AAF, 4-AAF, steroids)
Binucleating growth (development, phenobarbital, chlorinated
organochemicals)
Diploid growth (neoplastic growth)
of the method is that DNA-incorporated BrdU will re-
duce the binding and hence quench the fluorescence
yield from the DNA-staining dye Hoechst 33258, giving
rise to intermediary peaks ofDNA-synthesizing cells (S
phase and G2) in flow cytometric DNA histograms (53).
Figure 2 shows how this methodology has been ap-
plied to normal, regenerating livers. Twenty-three
hours after PH, many hepatocytes are actively syn-
thesizing DNA as indicated by the elevated baseline
fluorescence between the major nuclear DNA peaks
(Fig. 2A). In histograms from BrdU-labeled cells, the
DNA-synthesizing nuclei are evident as one quenched
tetraploid peak (in the hyperdiploid position) and one
quenched octoploid peak (in the hypertetraploid posi-
tion), representing labeled nuclei of diploid and tetra-
ploid origin, respectively, in late S and G2 phase ofthe
cell cycle (Fig. 2B). It is noteworthy that the octoploid
peak observed in Figure 2A is virtually absent in BrdU-
labeled nuclei, showing that it represents a tetraploid
G2 fraction rather than a true octoploid (i.e., G1) pop-
ulation. There is no fluorescence in the hyperoctoploid
region, i.e., proliferating 8N nuclei are not detectably
present.
The fate of the labeled nuclei after cell division can
be followed by allowing a chase period after cessation
of BrdU incorporation. Figure 2C shows that most of
the labeled tetraploid nuclei have been shifted to a sub-
tetraploid position (i.e., quenched tetraploid DNA con-
tent), indicating that nuclear division has occurred. The
HEPATOCELLULAR CARCINOMA-
16 MO. AFTER PH + 2-AAF
BrdU 60h
+12h chase
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appearance ofquenched diploid nuclei is less extensive,
reflecting the fact that a major fraction of the diploid
nuclei originally reside in binucleated cells and give rise
to tetraploid nuclei, which retain their position in the
histogram following DNA synthesis and division. The
quenched tetraploid nuclei observed after a chase thus
have mixed origins that cannot be resolved with the
present method. The reappearance of the unquenched
8N peak during the chase period reflects the entry of
tetraploid nuclei into S and G2 in the absence of BrdU
incorporation.
When BrdU/Hoechst flow cytometry is applied to he-
patocellular tumors, an entirely different result is ob-
tained. We have deliberately chosen to analyze slow-
growing tumors from old rats, in which a significant
fraction of tetraploid nuclei are present. As shown in
Figure 3, following a 60-hr BrdU pulse and a 12-hr
chase, labeled nuclei are found virtually exclusively in
the quenched diploid region of the histogram. About
one-halfofthese are nonparenchymal nuclei (which con-
stitute a significant fraction ofthe labeled tumor nuclei
after long-term labeling), but the remaining halfare of
bona fide hepatocellular (tumor) origin. In other words,
only the diploid tumor nuclei show significant prolifer-
ative activity. This phenomenon, which has been con-
sistently observed inthe tumorswehaveanalyzed, sup-
ports the notion of tetraploid cells as a subterminally
differentiated phenotype with a limited growth poten-
tial. Inhepatocellulartumors, thisgrowthpotentialmay
eventually become exhausted, leaving the tetraploid
cells as a proliferatively silent (but long-lived) subpo-
pulation. Alternatively, some renewal ofthe tetraploid
population may take place, but at a rate too low to be
detected by the present methods.
In contrast, the diploid hepatocellular tumor nuclei
have a labeling index that is high compared to the rate
of tumor growth. The extensive cellular turnover that
has been described in hepatocellular tumors (8) would
thus seem to be confined to this diploid fraction. The
proliferative polymorphism of hepatocellular tumors
may be an aspect of tumor differentiation worthy of
further study. In any event, the limitation ofdetectable
proliferative activity to the diploid fraction ofthetumor
nuclei underscores the importance of a diploid growth
pattern as a probably essential aspect ofthe neoplastic
liver cell phenotype.
Our studies thus suggest that at least three different
modes of hepatocellular proliferation may exist (Table
8). Mononucleating growth is observed during liver re-
generation and after treatment with 2-AAF or 4-AAF
and probably after steroid treatment (48). This type of
growth is characterized by divisional proliferation of
both diploid and tetraploid hepatocytes, but there is
essentially no binucleation and hence no progressive
polyploidization ofthetissue (apartfromapossible tran-
sient elevation ofthe tetraploid fraction as residual bin-
ucleated cells undergo division). Binucleating growth is
occurring during normal liver development and after
stimulation by compounds such as phenobarbital (39) or
chlorinated organochemicals (48,54). Binucleation is a
regular feature ofthis growth pattern, resulting in pro-
gressive tissue polyploidization and the maintenance of
a binucleated cell fraction. Diploid growth, i.e., divi-
sionalproliferation ofdiploid hepatocytes, isthe pattern
characteristic of neoplastic growth. It may have the
virtue ofmaintaining a high growth capacity as well as
a large population ofpotential stem cells capable ofex-
pressing the further mutational changes thought to be
involved in tumor progression.
The possibility should be considered that the mon-
onucleating growth pattern may gradually develop into
a predominantly diploid growth pattern as a result of
exhaustionoftheproliferative potentialofthetetraploid
cells. If so, the number of basic hepatocellular growth
patterns may be reduced by one. In the adult rat liver,
binucleatinggrowthwould appeartobe the constitutive
pattern, while the other modes ofgrowth are mobilized
byspecific stimuli. Replacementofbinucleatingbymon-
onucleating growth asthe newconstitutive pattern may
be an early and essential event in liver carcinogenesis.
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